Though immunotherapy via blocking PD-1/PD-L1 interaction is usually effective to partially reinvigorate the CD8+ T cells inside tumor, unfortunately, in advanced ccRCCs there were no association between CD8+ T cell infiltration and clinical benefit to anti-PD-1 therapy (32, 52, 53). This evidence concerns the gene PDCD1 and neoplasm.